Details of the Drug
General Information of Drug (ID: DMH1M6N)
Drug Name |
ORG2058
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
IJLXLZGJDSJGIQ-BILPMHSYSA-N; Org-2058; Org 2058; CHEMBL2311103; 24320-06-7; (8R,9S,10R,13S,14S,16R,17S)-16-ethyl-17-(2-hydroxyacetyl)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; O-2058; [3H]ORG2058; [3H]-ORG2058; A)-16-ethyl-21-hydroxy-19-norpregn-4-ene-3,20-dione; AC1Q6OBA; AC1L3O6Q; SCHEMBL3273165; GTPL3454; GTPL3453; 16alpha-Ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione; BDBM50422735; (16alpha)-16-Ethyl-21-hydroxy-19-norpregn-4-ene-3,20-dione; 19-Norpregn-4-ene-3,20-dione,; ORG-2058; ORG 2058
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure |
![]() |
|||||||||||||||||||
3D MOL is unavailable | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 344.5 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 3.8 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References